Visiopharm Broaden its Diagnostic Digital Pathology Solution with Oncotopix Scan

November 27th, 2017

Visiopharm has entered an agreement with HAMAMATSU to sell their portfolio of slide scanners, co-branded as Oncotopix® Scan, for clinical customers in Europe.

For many diagnostic pathology labs, implementing Digital Pathology is a major and often disruptive step. They are looking for a partner that can provide complete solutions in a way that is incremental, scalable, cost efficient and risk free in each step.

Read more

Visiopharm Wins Prestigious Award 

February 11th, 2017

We are proud to announce that we have received this prestigious “Børsen Gazelle Award” for the second time.

To receive the Gazelle Award, a company must be among the most successful companies across all industries in Denmark. Have demonstrated positive growth and have doubled revenue over a period of four financial years. The growth measure is based on net sales. If this is not disclosed in the annual report, the gross profit is used instead. 

We are excited to accept this prestigious award and would like to thank Børsen for this acknowledgement. 

Gazelle 2017 rgb transparent

DICOM - A Reality in Digital Pathology Workflows 

October 2nd, 2017

Just as for other medical fields, DICOM is expected to play a significant role in pathology as a universal and fundamental standard in digital medical imaging. The value chain of solution components in a digital pathology lab is both long and complex, which makes the adoption of standards as DICOM all the more important.

"One of the visions driving DICOM in general is to give users the freedom to choose the best-of-breed solution components, rather than being tied to single vendor", says Mikael Wintel who has been one of the driving forces behind the adaptation of the DICOM standard to the digital pathology field, through his work as co-chair of Working Group 26. Mikael Wintell is also panelist at the upcoming DICOM Digital Pathology Connect-a-thon at Pathology Visions.

Read more

Neagen and Visiopharm announce new Technical Integration between image analysis and PACS to meet demands from pathologists

Hørsholm – Denmark, September 5th, 2017 - Neagen and Visiopharm today announce an integration which improves the data quality of cancer patient samples in a single PACS-driven digital pathology workflow also offering time and cost savings. This in term enhances quality for pathologists working in cancer research and diagnostics and benefits the patients.

Visiopharm is a worldwide leader of Augmented Pathology™ within tissue research and diagnostics and Neagen offers a true vendor neutral enterprise imaging system based on worldwide DICOM standard.

Read more